United Therapeutics Revenue 2006-2019 | UTHR

United Therapeutics revenue from 2006 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
United Therapeutics Annual Revenue
(Millions of US $)
2019 $1,449
2018 $1,628
2017 $1,725
2016 $1,599
2015 $1,466
2014 $1,289
2013 $1,117
2012 $916
2011 $743
2010 $593
2009 $359
2008 $281
2007 $211
2006 $160
2005 $116
United Therapeutics Quarterly Revenue
(Millions of US $)
2019-12-31 $311
2019-09-30 $402
2019-06-30 $374
2019-03-31 $363
2018-12-31 $381
2018-09-30 $413
2018-06-30 $445
2018-03-31 $389
2017-12-31 $465
2017-09-30 $446
2017-06-30 $445
2017-03-31 $371
2016-12-31 $409
2016-09-30 $408
2016-06-30 $413
2016-03-31 $369
2015-12-31 $405
2015-09-30 $386
2015-06-30 $347
2015-03-31 $328
2014-12-31 $346
2014-09-30 $330
2014-06-30 $323
2014-03-31 $289
2013-12-31 $289
2013-09-30 $302
2013-06-30 $281
2013-03-31 $245
2012-12-31 $244
2012-09-30 $242
2012-06-30 $226
2012-03-31 $204
2011-12-31 $195
2011-09-30 $202
2011-06-30 $184
2011-03-31 $163
2010-12-31 $161
2010-09-30 $169
2010-06-30 $135
2010-03-31 $129
2009-12-31 $98
2009-09-30 $97
2009-06-30 $84
2009-03-31 $80
2008-12-31 $76
2008-09-30 $75
2008-06-30 $69
2008-03-31 $62
2007-12-31 $60
2007-09-30 $59
2007-06-30 $52
2007-03-31 $40
2006-12-31 $46
2006-09-30 $40
2006-06-30 $40
2006-03-31 $33
2005-12-31 $30
2005-09-30 $33
2005-06-30 $30
2005-03-31 $23
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $4.070B $1.449B
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics (UT) has an overarching commitment to environmental sustainability. The company's product candidates include Adcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability in PAH patients. Orenitram is a prostacyclin vasodilator indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $54.432B 31.49
Takeda Pharmaceutical (TAK) Japan $45.999B 8.06
Astellas Pharma (ALPMY) Japan $27.558B 13.76
Eisai (ESALY) Japan $19.334B 36.02
UCB SA (UCBJF) Belgium $15.687B 0.00
Grifols, S.A (GRFS) Spain $13.187B 16.39
Merck (MKGAF) Germany $12.536B 16.44
Ono Pharmaceutical (OPHLF) Japan $9.254B 19.78
Neurocrine Biosciences (NBIX) United States $7.917B 219.95
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $7.874B 0.00
Catalent (CTLT) United States $7.164B 29.48
Ionis Pharmaceuticals (IONS) United States $6.754B 20.47
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.361B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $5.544B 6.76
Orion OYJ (ORINY) Finland $5.269B 23.61
STADA ARZNEIMI (STDAF) Germany $4.685B 0.00
Forty Seven (FTSV) United States $4.597B 0.00
IPSEN SA ADR (IPSEY) France $4.543B 0.00
Evotec AG (EVTCY) Germany $3.428B 55.29
Hypermarcas (HYPMY) Brazil $3.424B 10.41
Nektar Therapeutics (NKTR) United States $2.994B 0.00
FibroGen (FGEN) United States $2.866B 0.00
PTC Therapeutics (PTCT) United States $2.666B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $2.655B 49.28
Taro Pharmaceutical Industries (TARO) Israel $2.418B 9.78
ChemoCentryx (CCXI) United States $2.402B 0.00
Xencor (XNCR) United States $1.649B 67.35
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.620B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.561B 18.98
Theravance Biopharma (TBPH) Cayman Islands $1.439B 0.00
Sage Therapeutics (SAGE) United States $1.347B 0.00
USANA Health Sciences (USNA) United States $1.344B 14.11
Corcept Therapeutics (CORT) United States $1.335B 14.94
Pacira Pharmaceuticals (PCRX) United States $1.295B 35.40
Karyopharm Therapeutics (KPTI) United States $1.168B 0.00
Heron Therapeutics (HRTX) United States $1.056B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.010B 31.30
Zogenix (ZGNX) United States $1.010B 0.00
Akebia Therapeutics (AKBA) United States $0.874B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $0.859B 11.96
Esperion Therapeutics (ESPR) United States $0.846B 0.00
CLINIGEN GP (CLIGF) United Kingdom $0.781B 0.00
Endo (ENDP) Ireland $0.721B 1.33
ImmunoGen (IMGN) United States $0.596B 0.00
Tilray (TLRY) Canada $0.576B 0.00
Translate Bio (TBIO) United States $0.572B 0.00
Aerie Pharmaceuticals (AERI) United States $0.565B 0.00
Molecular Templates (MTEM) United States $0.561B 0.00
Collegium Pharmaceutical (COLL) United States $0.553B 0.00
Radius Health (RDUS) United States $0.550B 0.00
Portola Pharmaceuticals (PTLA) United States $0.504B 0.00
Indivior (INVVY) United States $0.397B 2.36
Siga Technologies (SIGA) United States $0.393B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.386B 15.84
Innate Pharma SA (IPHYF) France $0.385B 0.00
Ardelyx (ARDX) United States $0.378B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.365B 12.17
Corbus Pharmaceuticals Holdings (CRBP) United States $0.354B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.324B 0.00
Organogenesis Holdings (ORGO) United States $0.312B 0.00
Trillium Therapeutics (TRIL) Canada $0.301B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.301B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.299B 0.00
Calithera Biosciences (CALA) United States $0.286B 0.00
Lannett Co Inc (LCI) United States $0.285B 4.58
Harpoon Therapeutics (HARP) United States $0.277B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.263B 0.00
DURECT (DRRX) United States $0.260B 0.00
Flexion Therapeutics (FLXN) United States $0.256B 0.00
Ocular Therapeutix (OCUL) United States $0.251B 0.00
TherapeuticsMD (TXMD) United States $0.250B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.246B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.243B 0.00
Concert Pharmaceuticals (CNCE) United States $0.232B 0.00
Rafael Holdings (RFL) United States $0.186B 0.00
CASI Pharmaceuticals (CASI) United States $0.185B 0.00
Recro Pharma (REPH) United States $0.166B 0.00
OptiNose (OPTN) United States $0.164B 0.00
PROFOUND MEDICL (PROF) Canada $0.157B 0.00
MEI Pharma (MEIP) United States $0.155B 0.00
Jounce Therapeutics (JNCE) United States $0.145B 2.61
Nature's Sunshine Products (NATR) United States $0.140B 17.58
La Jolla Pharmaceutical (LJPC) United States $0.140B 0.00
Taiwan Liposome (TLC) Taiwan $0.137B 0.00
KalVista Pharmaceuticals (KALV) United States $0.135B 0.00
VAXART, INC (VXRT) United States $0.120B 0.00
Redhill Biopharma (RDHL) Israel $0.104B 0.00
CannTrust Holdings (CTST) Canada $0.090B 0.00
IMV INC (IMV) Canada $0.086B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.084B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.081B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.081B 0.00
Champions Oncology (CSBR) United States $0.080B 0.00
SCYNEXIS (SCYX) United States $0.079B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.074B 0.00
CTI BioPharma (CTIC) United States $0.070B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.068B 0.00
Biomerica (BMRA) United States $0.065B 0.00
CV Sciences (CVSI) United States $0.064B 0.00
Xeris Pharmaceuticals (XERS) United States $0.064B 0.00
Aquestive Therapeutics (AQST) United States $0.062B 0.00
Otonomy (OTIC) United States $0.060B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.056B 17.62
ALLERGY THERAPT (AGYTF) United Kingdom $0.055B 0.00
Nivalis Therapeutics (ALPN) United States $0.054B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.052B 0.00
Onconova Therapeutics (ONTX) United States $0.048B 0.00
Infinity Pharmaceuticals (INFI) United States $0.047B 0.00
Aclaris Therapeutics (ACRS) United States $0.046B 0.00
PharmAthene (ALT) United States $0.045B 0.00
GTx (ONCT) United States $0.044B 0.00
Natural Alternatives (NAII) United States $0.043B 19.47
MediWound (MDWD) Israel $0.040B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.040B 133.57
Sundial Growers (SNDL) Canada $0.040B 0.00
Iterum Therapeutics (ITRM) Ireland $0.036B 0.00
Neos Therapeutics (NEOS) United States $0.036B 0.00
Forward Pharma (FWP) Denmark $0.035B 0.00
PolarityTE (PTE) United States $0.035B 0.00
ElectroCore (ECOR) United States $0.031B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.031B 0.00
Heat Biologics (HTBX) United States $0.029B 0.00
Jaguar Animal Health (JAGX) United States $0.026B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.024B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.023B 0.00
ProPhase Labs (PRPH) United States $0.022B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.021B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.021B 0.00
Cardiome Pharma (CORV) Canada $0.021B 0.00
Lipocine (LPCN) United States $0.020B 0.00
Mannatechorporated (MTEX) United States $0.018B 5.78
Bio-Path Holdings (BPTH) United States $0.018B 0.00
Novan (NOVN) United States $0.018B 0.00
Cyanotech (CYAN) United States $0.013B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.012B 0.00
Shineco (TYHT) China $0.012B 0.00
China SXT Pharmaceuticals (SXTC) China $0.011B 0.00
Vical (BBI) United States $0.011B 0.00
KemPharm (KMPH) United States $0.010B 0.00
Regulus Therapeutics (RGLS) United States $0.010B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.009B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.007B 0.00
Midatech Pharma (MTP) United Kingdom $0.006B 0.00
HANCOCK JAFFE (HJLI) United States $0.006B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.006B 0.00
RXi Pharmaceuticals (PHIO) United States $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Flex Pharma (SLRX) United States $0.003B 0.00